Page 41 - Rna News Today

Continued technology platform validation with extended preliminary data from older adults in ongoing Phase 1 studies in COVID-19 and fluCOVID-19: monovalent modified mRNA construct CV0501 successfully

Read more about Blast at Iran military plant caused by drone attack - state media on Devdiscourse

Read more about Strong quake in northwest Iran kills at least three people on Devdiscourse

"An explosion has occurred in one of the military centres affiliated to the Ministry of Defense," the deputy head of security for Isfahan Governorate Mohammad Reza Jan-Nesari told the semi-official Fars News Agency, according to CNN.

Dublin, Jan. 25, 2023 (GLOBE NEWSWIRE) -- The "CRISPR Technology: Global Markets" report has been added to ResearchAndMarkets.com's offering. The...

On the journey from gene to protein, a nascent RNA molecule can be cut and joined, or spliced, in different ways before being translated into a protein.

Honeybees, which pollinate one-third of the crops Americans eat, face many threats, including infectious diseases.On January 4, 2023, a Georgia biotechnology company called Dalan Animal Health announced that it had received a conditional license from the US Department of Agriculture for a vaccine designed to protect honeybees against American foulbrood, a highly destructive infection.To receive a conditional license, which usually lasts for one year and is subject to further evaluation by the US...

Inflp inflinflation -- ths allies from australia to singapore are stepping up, cooperating, and forging a new way forward. the united states is in remarkably good shape. the federal reserve appears to be on the right track in tackling inflation. its possible that the u.s. could avoid a recession all together, or have one that is short and shallow. biden has signed perhaps the largest long-term investments in the american economy since the p ereran of lyndon john cent century ago. american techno...

Experimental jab is similar to more effective foreign vaccines and is designed to target the Omicron variant.

Kaneka Corporation (Headquarters: Minato-ku, Tokyo; President: Minoru Tanaka)(TOKYO:4118) has decided to increase its GMP*1 manufacturing capacity for mRNA*2 in Kaneka Eurogentec S.A. (Headquarters: